Literature DB >> 12710122

The timing of a positive test result for heparin-induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases.

Majed A Refaai1, Elizabeth M Van Cott, Michael Laposata.   

Abstract

We studied the timing of a positive heparin-induced thrombocytopenia (HIT) test result relative to changes in platelet count and anticoagulant use. We obtained platelet counts in 100 consecutive HIT+ cases before, during, and after heparin therapy; 43 cases met study criteria and were included in study part 1. In part 2, platelet counts at the time of the HIT test in 2 groups (100 each HIT+ and HIT- cases) were compared. In part 1, cases could be divided into 4 groups based on the diagnosis of HIT relative to platelet counts (1, within 1-2 days of a major drop in platelet count [11.6%]; 2, after > 2 days of a major fall in platelet count [41.9%]; 3, in patients with already low platelet counts [27.9%]; 4, after platelet count was rising [18.6%]). In study part 2, the mean platelet counts for the HIT+ and HIT- groups were almost identical. HIT should be suspected in any thrombotic patient who had a previous decline in platelet count, has a low platelet count, or has a rising platelet count after a previous decline in association with heparin exposure. In study part 2, 1 platelet count value at the time of the HIT test did not provide useful information.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12710122     DOI: 10.1309/KM2Y-9H9T-P6DA-59MT

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

Review 1.  New concepts in heparin-induced thrombocytopenia: diagnosis and management.

Authors:  Sarah A Spinler
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

2.  Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay.

Authors:  Majed A Refaai; Grace Conley; Thomas L Ortel; John L Francis
Journal:  Int J Lab Hematol       Date:  2019-04-15       Impact factor: 2.877

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.